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ere in the 21
st
 century we have a 
standard vision of how medical care is 
supposed to work in developed 
countries: you fall ill, visit a doctor, receive 
treatment, and are cured. Deviations from this 
model are explained away by lack of access to 
good healthcare: long wait times to get a doctor’s 
appointment or subsequent testing, the expense 
of private health insurance, or the refusal of 
universal healthcare systems to fund cutting-
edge treatments [1]. Interventions to remedy the 
above issues rest on the assumption that, given 
better access to the best that healthcare has to 
offer, few would walk away from treatment 
unhealed. This view is fuelled by the belief that 
modern medicine has at its disposal an arsenal of 
“magic bullets,” drugs that are both: 
 
I.   Highly specific, meaning that they target only 
the intended disease, reducing side effects, 
and 
II.   Highly effective, meaning that they restore 
the patient to normal health [2]. 
  
A classic example of a magic bullet is penicillin 
for bacterial infections: the drug binds to an 
enzyme found only in bacteria and causes them 
to die without interfering with human systems. 
However, according to a growing army of 
skeptics, including philosopher of science Jacob 
Stegenga, such specificity and effectiveness are 
rare among modern drugs, and this has 
implications for how medical research should 
progress. 
 
In his upcoming book, Stegenga argues that 
modern medicine has on the whole produced few 
“magic bullets” [2]. On the whole, many of the 
most commonly prescribed modern drugs — 
including statins and antidepressants — are only 
mildly effective at curing the conditions they are 
meant to target, and side effects are much worse 
than the research suggests. For example, taking 
statins for five years on average saves the life of 
only 1 in 83 patients with prior heart disease, but 
1 in 10 of these patients develop muscle damage 
[3]. This means that on the whole, we spend an 
enormous amount of money on drugs that have 
very little benefit. 
Modern medicine has on the whole 
produced few ‘magic bullets.’  … This 
means that on the whole, we spend an 
enormous amount of money on drugs that 
have very little benefit. 
Stegenga outlines several reasons for this state 
of affairs, foremost among	  them the fact that the 
drug development and approval systems are 
inherently flawed. Rampant publication bias 
means that papers presenting positive findings 
are published more often than papers that have 
negative findings. Clinical trials often don’t last 
long enough to pinpoint long term negative side 
effects. Peer review doesn’t reliably weed out 
results that cannot be replicated. And, most 
damning of all, he writes, strategies designed to 
test medical interventions—such as randomized 
controlled trials (RCTs) and meta-analyses—are 
inherently malleable and open to manipulation, 
whether conscious or unconscious [5]. 
 
Furthermore, the structure of the pharmaceutical 
marketplace means that drug companies do not 
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focus on the research that can do the broadest 
benefits. Companies spend R&D funding on 
creating competitors to profitable drugs, rather 
than channeling these resources into finding 
drugs for medical needs that are as yet unmet. 
This is particularly true for illnesses that largely 
affect people in the developing world who are 
unable to pay for expensive treatment. [6] Even 
though competition through so-called “me-too” 
drugs helps reduce prices, drug companies claim 
that they have to stay high enough to offset the 
cost of developing drugs that don’t end up on the 
market [3]. 
According to Stegenga, we’re better off 
diverting funding towards non-medical 
interventions that aim to prevent diseases 
in the first place.  Most diseases are too 
biologically complex for ‘magic bullet’ 
solutions. 
According to Stegenga, we’re better off diverting 
funding towards non-medical interventions that 
aim to prevent diseases in the first place. Most 
diseases are too biologically complex for “magic 
bullet” solutions: many have more than one 
causal basis, making a single drug insufficient. 
The fact that biological pathways are highly 
interconnected also makes it more likely that a 
drug will act where it is not supposed to, 
resulting in limited efficacy with unwanted side 
effects. [2] On a worldwide scale, ensuring 
access to basics such as clean drinking water will 
have the largest effect on the global disease 
burden, but Stegenga also highlights the 
importance of better-quality research into other 
non-pharmaceutical options, such as nutrition, 
stress reduction and physical therapy. 
Interventions in this area are often low-cost and 
highly effective compared to drugs, but research 
into their effects (especially in the case of 
nutrition) is often retrospective, skewed by 
corporate interests, and even more malleable 
than pharmaceutical RCTs [6]. 
 
There are a number of policy interventions that 
could address these issues. Policies that divert a 
fraction of the money spent on drug research 
towards lifestyle impacts — which are largely not 
patentable and therefore overlooked — could 
help solidify the evidence base for these 
interventions and greatly improve strategies for 
patient care. This is not to say that 
pharmaceutical research should be completely 
abolished; rather, money that we do spend on 
pharmaceuticals should go towards truly novel 
research rather than “me-too” drugs that do little 
to improve patient outcomes compared to 
existing drugs. Researchers should also focus 
greater attention on diseases that are less 
biologically complex, or on simple solutions to 
combat illnesses in the developing world, which 
come at a lower cost. Stricter regulations would 
deny approval to drugs that target conditions for 
which there is already a viable treatment, unless 
they confer a significant benefit over existing 
medications, incentivizing companies to bring 
drugs to market based on their effectiveness 
rather than marketing potential [6]. 
 
Conclusion 
 The main point to be taken from Stegenga’s 
research is that claims of drug efficacy are often 
vastly overstated, with the media presenting 
claims of new “game-changers” almost daily. 
These claims cloud the fact that for millions of 
people, ranging from cancer patients to sufferers 
of chronic pain, medicines are incredibly costly 
and have a limited effect. It is crucial that those 
with the power to fund and regulate health 
interventions internalize the improbability of 
finding magic bullet cures, and increase funding 
for preventative interventions that will provide 
the best cost-benefit outcome for patient care. 
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